Urine Testing Articles & Analysis
-
miR Scientific to Present the Prostate Cancer Application of its Liquid Biopsy Disease Management Platform at the 39th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 11, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company whose purpose is to transform global cancer management by providing early and highly accurate detection, characterization and monitoring of disease, announced today that its Chairman & CEO, Sam Salman, will be virtually presenting at the 39th Annual J.P. Morgan Healthcare Conference. Mr. Salman will introduce ...
-
miR Scientific to Present the Award-Winning Prostate Cancer Application of its Liquid Biopsy Disease Management Platform at the Jefferies Virtual Healthcare Conference
NEW YORK, June 3, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company dedicated to transforming global cancer management by providing early and highly accurate detection, characterization and monitoring of disease, announced today that its Chairman & CEO, Sam Salman, will be presenting at the Jefferies Virtual Healthcare Conference. Mr. Salman will discuss the planned commercial ...
-
miR Scientific to Present the Prostate Cancer Application of its Liquid Biopsy miR Disease Management Platform® at the 12th Annual Prostate Cancer Awareness Day (PCAD) at the Massachusetts State House
NEW YORK, Feb. 25, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company whose purpose is to transform global cancer management by providing early and highly accurate detection, characterization and monitoring of disease, announced today that its Chairman & CEO, Sam Salman, will be virtually presenting at the 12th Annual Prostate Cancer Awareness Day at the Massachusetts State House ...
-
Nucleix’s BE Safe @Home Project Brings Bladder Cancer Surveillance to Patients’ Homes During COVID-19 Pandemic and Beyond
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, recently announced the launch of its BE Safe @Home project to bring surveillance for recurrence of non-muscle invasive bladder cancer (NMIBC) to patients’ homes with its Bladder EpiCheck® urine test. This initiative was developed after ...
By Nucleix Ltd.
-
Nucleix’s BE Safe @Home Project Brings Bladder Cancer Surveillance to Patients’ Homes During COVID-19 Pandemic and Beyond
-Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, recently announced the launch of its BE Safe @Home project to bring surveillance for recurrence of non-muscle invasive bladder cancer (NMIBC) to patients’ homes with its Bladder EpiCheck® urine test. This initiative was developed after consulting with world-leading urologists in an ...
By Nucleix Ltd.
-
U-M-led study adds to understanding of how phthalate exposure impacts pregnancy
In recent years, scientists have linked chemicals known as phthalates with complications of pregnancy and fetal development. Now, a study led by researchers at the University of Michigan School of Public Health sheds light on the mechanism that may be to blame. Phthalates are chemicals used to make plastic materials more flexible and can also be found in personal care products such as perfumes, ...
-
miR Scientific and Leonie Hill Capital Announce Collaboration to Introduce Breakthrough Urine Liquid Biopsy Prostate Cancer Test in Singapore
High demand seen for effective disease management platform for second most common cancer in Singaporean men NEW YORK and SINGAPORE, March 28, 2022 /PRNewswire/ -- miR Scientific, a New York-based healthcare company dedicated to transforming global cancer management, and Leonie Hill Capital, a Singapore-based organization focused on large-scale, sophisticated healthcare access and distribution, ...
-
OncoDiag raises €2.5M ($3M) to develop its diagnostic testing for early detection of cancer
OncoDiag, a company specializing in the development of diagnostic tests for the early detection of cancer, today announces that it has raised €2.5 million ($3M) in a Series A round of funding. Of this, €1.5 million ($1.8M) was from several groups of business angels, including a number of historic investors: Angels Santé, Business Angels des Grandes Ecoles (BADGE), and Normandie ...
By OncoDiag
-
Nucleix Presents Clinical Data at EAU21 Virtual Congress Which Demonstrates Promising Advances in the Care of Bladder Cancer Patients
SAN DIEGO & REHOVOT, ISRAEL--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from two abstracts featuring its Bladder EpiCheck® test at the 36th Annual European Association of Urology (EAU) Virtual Congress. The first abstract titled, “Real world evidence of alternating cystoscopy/cytology ...
By Nucleix Ltd.
-
miR Scientific and Puerto Rico Government team up for Prostate Cancer Prevention Day, to battle the number one cause of cancer-related death among men in the island
NEW YORK and SAN JUAN, Puerto Rico, Sept. 1, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company focused on transforming global cancer management, the Governor of Puerto Rico, Pedro Pierluisi, and the Puerto Rico Health Insurance Administration ("ASES") join forces today to officially make September 1 "Prostate Cancer Prevention Day". This urgent awareness team effort occurs while the ...
-
Alternating Nucleix’s Bladder EpiCheck® With Standard Surveillance Can Reduce Burden on Patients and Healthcare Systems
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced the publication of an analysis highlighting that Bladder EpiCheck® can reduce both patient burden and healthcare system costs in the U.S. and European countries for low grade intermediate risk non-muscle invasive bladder cancer ...
By Nucleix Ltd.
-
Bio-Techne`s Exosome Diagnostics Laboratory Announces CE-IVD Certification for Exodx Prostate Test
Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in vitro diagnostic (IVD) version of the ExoDx™ Prostate test (EPI) kit enabling self-certification as CE-IVD as of March 22, 2021. Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has ...
-
miR Scientific is proud to announce the commercial availability of the miR Sentinel™ Prostate Cancer Test
NEW YORK, July 13, 2022 /PRNewswire/ -- miR Scientific, LLC announces the miR Sentinel™ Prostate Cancer Test is now commercially available in the United States, Puerto Rico and select international markets. miR Sentinel™ is a novel, urine-based, molecular test that analyzes small non-coding RNA using a proprietary biostatistical algorithm. The miR Sentinel™ Test assesses the ...
-
miR Scientific launches "Can do Blue" on September 1, 2022, as Prostate Cancer Awareness Month
NEW YORK and SAN JUAN, Puerto Rico, Aug. 18, 2022 /PRNewswire/ -- miR Scientific, LLC announced the launch of national event #CanDoBlue to create awareness of the need for widespread prostate cancer testing during the 2022 Prostate Cancer Awareness Month (also known as "PCAM"). On September 1, New York, New Jersey, Chicago, and Puerto Rico will simultaneously light up dozens of landmarks and ...
-
INTIN - Creator of a Male Sperm Analyzer and Ovulation Tester
The global fertility services market is estimated to reach $45 billion by 2027. This opens up a massive opportunity for startups to innovate in the space. One of the most innovative startups is INTIN, the creator of a male sperm analyzer called OVIEW-M, which uses the camera on a smartphone to analyze sperm counts. They are also the creators of an at-home ovulation tester that uses salvia instead ...
By INTIN Inc.
-
Winner announcement of EACR & Novosanis Research Grant: Cancer Biomarker Detection in Urine
We are pleased to announce that Dr Barbara Guinn from University of Hull UK is the winner of the EACR & Novosanis Grant for Cancer Biomarker Detection in Urine. The grant awards the most impactful proposal in cancer related research using urine as a sample type, which has shown to be an emerging non-invasive liquid biopsy. For urine sample collection, the Colli-Pee device will be provided by ...
By Novosanis NV
-
miR Scientific Presents Groundbreaking Data on the Exceptional Accuracy of its Prostate Cancer Liquid-Biopsy Test
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Data presented from a cross-validation study at the American Urological Association's (AUA) 2021 Annual Meeting confirms that the miR Sentinel® Prostate Cancer Test can detect and risk-classify prostate cancer at the molecular level with predictive accuracy of over 90%, based on a single urine sample. This validation study follows and confirms the ...
-
NanoExplore Recruiting Companies in Certain EU Member States to Participate in Study of Occupational Exposure to Nanomaterials
The NanoExplore project, which is supported by the European Union’s (EU) LIFE program, aims at an integrated approach for exposure and health effects monitoring of engineered and incidental nanomaterials in occupational settings. The project is currently in its pilot phase. According to NanoExplore, the pilot study will take place following a two-step procedure over two field campaigns ...
-
Bio-Techne and Hall of Famer Cal Ripken Jr -Announce Partnership to Raise Awareness and Education to Empower Men With Prostate Cancer
Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with Hall of Famer and baseball's all-time "Iron Man", Cal Ripken Jr. This year marks 25 years since Ripken played in his 2,131st consecutive game, eclipsing the thought to be unbreakable record of 2,130 set by the legendary Lou Gehrig. Recently the 21-year Major ...
-
Consuming Canned Soups Elevates BPA Levels, Study Finds
Harvard researchers have found that people who ate one serving of canned food daily over the course of five days had a tenfold increase of bisphenol-A, or BPA, in their bodies, according to the New York Times. Past research indicates that BPA can mimic the hormone estrogen, and thus it is considered to be an endocrine disruptor. Some scientists claim that BPA is not a health threat, but ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you